All Updates

All Updates

icon
Filter
Partnerships
Intellia and Regeneron expand existing research collaboration to develop gene-editing therapies
Human Gene Editing
Oct 3, 2023
This week:
Product updates
Nintendo ventures into MMOs with new Switch Online game playtest
Metaverse Experience Platforms
Yesterday
Product updates
HP releases texture library for 3D printing with CoreTechnologie 4D Additive
Additive Manufacturing
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Smart Factory
Oct 21, 2024
Product updates
xAI launches API for third-party developers to access Grok models
Foundation Models
Oct 21, 2024
Partnerships
Nava Benefits partners with OpenAI to launch AI-powered benefits assistant
Foundation Models
Oct 21, 2024
Product updates
IBM releases Granite 3.0 AI models for enterprise use
Foundation Models
Oct 21, 2024
Partnerships
Honeywell partners with Google to bring Gemini AI to industrial sector
Foundation Models
Oct 21, 2024
M&A
Inflection AI acquires Boundaryless for undisclosed sum to accelerate enterprise AI deployments
Foundation Models
Oct 21, 2024
Industry news
News Corp sues Perplexity AI for alleged copyright infringement
Generative AI Applications
Oct 21, 2024
Product updates
Haiper debuts new video generation model
Generative AI Applications
Oct 21, 2024
Human Gene Editing

Human Gene Editing

Oct 3, 2023

Intellia and Regeneron expand existing research collaboration to develop gene-editing therapies

Partnerships

  • Massachusetts-based gene-editing biotech company Intellia Therapeutics and New York-based biotech company Regeneron Pharmaceuticals have expanded the existing research collaboration (entered in April 2016) to develop gene-editing therapies for neurological and muscular diseases.

  • The collaboration will leverage Regeneron's antibody-targeted adeno-associated virus (AAV) vectors and Intellia's Nme2 Cas9 system to modify target genes in non-liver tissues. The companies will initially focus on two non-liver targets, and each company will have the opportunity to lead the development and commercialization of product candidates for one target.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.